IBRX
ImmunityBio, Inc.
Price Chart
Latest Quote
$7.80
+0.48 (+6.56%)
Current Price
| Previous Close | $7.32 |
| Open | $7.34 |
| Day High | $7.96 |
| Day Low | $7.26 |
| Volume | 16,483,106 |
Stock Information
| Shares Outstanding | 1.05B |
| Total Debt | $1.12B |
| Cash Equivalents | $380.88M |
| Revenue | $140.98M |
| Net Income | $-854.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.17B |
| EPS (TTM) | $-0.85 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.91B |
| Sales | $140.98M |
| Income | $-854.53M |
| Book/sh | $-0.83 |
| Cash/sh | $0.36 |
| Employees | 684 |
Financial Ratios
| Quick Ratio | 6.24 |
| Current Ratio | 6.67 |
Returns & Margins
| ROA | -34.38% |
| Gross Margin | 99.34% |
| Operating Margin | -157.88% |
Ownership
| Insider Ownership | 62.48% |
| Institutional Ownership | 17.60% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 130.00 |
| P/S | 57.95 |
| P/B | -9.39 |
Analyst Data
| Recommendation | none |
| Target Price | $13.00 |
Technical Indicators
| SMA20 | $7.26 |
| SMA50 | $7.56 |
| SMA200 | $5.21 |
| RSI | 59.69 |
| ATR | 0.4511 |
| Shares Float | 394.05M |
| Short Float | 34.02% |
| Short Ratio | 9.31 |
| Volatility | 0.10 |
| Rel Volume | 1.34 |
Performance History
| Week | +16.07% |
| Month | +8.03% |
| Quarter | +5.19% |
| 6 Months | +275.00% |
| YTD | +286.14% |
| Year | +182.61% |
| 3 Years | +184.67% |
| 5 Years | -45.38% |
| 10 Years | +34.25% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $7.80 | 16,490,800 |
| 2026-06-23 | $7.32 | 11,316,400 |
| 2026-06-22 | $7.22 | 9,888,300 |
| 2026-06-18 | $7.36 | 14,372,400 |
| 2026-06-17 | $6.99 | 13,199,300 |
| 2026-06-16 | $6.72 | 12,797,600 |
| 2026-06-15 | $7.13 | 8,140,200 |
| 2026-06-12 | $7.10 | 8,793,800 |
| 2026-06-11 | $7.20 | 8,611,300 |
| 2026-06-10 | $6.98 | 9,421,100 |
| 2026-06-09 | $7.25 | 12,673,000 |
| 2026-06-08 | $7.17 | 11,387,000 |
| 2026-06-05 | $6.92 | 13,818,400 |
| 2026-06-04 | $7.29 | 9,612,100 |
| 2026-06-03 | $7.18 | 8,968,000 |
| 2026-06-02 | $7.23 | 13,723,400 |
| 2026-06-01 | $7.24 | 20,423,900 |
| 2026-05-29 | $7.52 | 15,617,400 |
| 2026-05-28 | $7.72 | 12,625,900 |
| 2026-05-27 | $7.89 | 14,532,400 |
| 2026-05-26 | $7.92 | 19,077,200 |
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guÊrin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
đ° Latest News
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying
Stocktwits âĸ 2026-06-24T02:17:10Z
Jim Cramer Says âLet ImmunityBio Be Your Speculationâ to a Caller
Insider Monkey âĸ 2026-06-19T13:35:27Z
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026
Insider Monkey âĸ 2026-06-11T01:15:19Z
3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth
Simply Wall St. âĸ 2026-06-08T17:36:56Z
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now
Insider Monkey âĸ 2026-06-06T00:13:20Z
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook
Simply Wall St. âĸ 2026-06-03T09:08:22Z
IBRX Stock Outlook After Q1 Results and a New FDA Review
Zacks âĸ 2026-05-29T17:25:00Z
ImmunityBio: Anktiva Explained and What Comes Next
Zacks âĸ 2026-05-29T17:21:00Z
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200
Insider Monkey âĸ 2026-05-29T06:42:01Z
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX)
Simply Wall St. âĸ 2026-05-28T19:03:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $753,000 | $0 | $0 | $0 |
| Cost Of Revenue | $753,000 | $0 | $0 | $0 |
| Total Revenue | $113,288,000 | $14,745,000 | $622,000 | $240,000 |
| Operating Revenue | $112,982,000 | $14,150,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $112,525,000 | $131,740,000 | $86,803,000 | $47,145,000 |
| Total Expenses | $369,315,000 | $358,927,000 | $361,986,000 | $350,857,000 |
| Other Income Expense | $14,256,000 | $82,464,000 | $-94,193,000 | $-5,862,000 |
| Other Non Operating Income Expenses | $-44,947,000 | $43,457,000 | $-38,426,000 | $-736,000 |
| Net Non Operating Interest Income Expense | $-109,836,000 | $-151,927,000 | $-128,336,000 | $-60,807,000 |
| Interest Expense Non Operating | $112,525,000 | $131,740,000 | $86,803,000 | $47,145,000 |
| Operating Expense | $368,562,000 | $358,927,000 | $361,986,000 | $350,857,000 |
| Total Other Finance Cost | - | $22,587,000 | $42,396,000 | $16,370,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-351,398,000 | $-413,564,000 | $-583,196,000 | $-416,567,000 |
| Net Interest Income | $-109,836,000 | $-151,927,000 | $-128,336,000 | $-60,807,000 |
| Interest Income | $2,689,000 | $2,400,000 | $863,000 | $2,708,000 |
| Normalized Income | $-410,601,000 | $-452,571,000 | $-534,981,303 | $-422,081,990 |
| Net Income From Continuing And Discontinued Operation | $-351,398,000 | $-413,564,000 | $-583,196,000 | $-416,567,000 |
| Total Operating Income As Reported | $-256,027,000 | $-344,182,000 | $-362,250,000 | $-351,298,000 |
| Net Income Common Stockholders | $-351,398,000 | $-413,564,000 | $-583,196,000 | $-416,567,000 |
| Net Income | $-351,398,000 | $-413,564,000 | $-583,196,000 | $-416,567,000 |
| Net Income Including Noncontrolling Interests | $-351,472,000 | $-413,645,000 | $-583,852,000 | $-417,320,000 |
| Net Income Continuous Operations | $-351,472,000 | $-413,645,000 | $-583,852,000 | $-417,320,000 |
| Pretax Income | $-351,607,000 | $-413,645,000 | $-583,892,000 | $-417,286,000 |
| Special Income Charges | $0 | $0 | $-886,000 | $-681,000 |
| Earnings From Equity Interest | $0 | $0 | $-7,549,000 | $-12,107,000 |
| Interest Income Non Operating | $2,689,000 | $2,400,000 | $863,000 | $2,708,000 |
| Operating Income | $-256,027,000 | $-344,182,000 | $-361,364,000 | $-350,617,000 |
| Gross Profit | $112,535,000 | $14,745,000 | $622,000 | $240,000 |
| Per Share | ||||
| Diluted EPS | $-0.38 | $-0.62 | $-1.15 | $-1.04 |
| Basic EPS | $-0.38 | $-0.59 | $-1.15 | $-1.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-3,303 | $1,466,010 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-282,760,000 | $-303,358,000 | $-430,359,000 | $-358,862,000 |
| Total Unusual Items | $59,203,000 | $39,007,000 | $-48,218,000 | $6,981,000 |
| Total Unusual Items Excluding Goodwill | $59,203,000 | $39,007,000 | $-48,218,000 | $6,981,000 |
| Reconciled Depreciation | $15,525,000 | $17,554,000 | $18,512,000 | $18,260,000 |
| EBITDA (Bullshit earnings) | $-223,557,000 | $-264,351,000 | $-478,577,000 | $-351,881,000 |
| EBIT | $-239,082,000 | $-281,905,000 | $-497,089,000 | $-370,141,000 |
| Diluted Average Shares | $919,863,000 | $700,443,000 | $508,636,000 | $399,900,000 |
| Basic Average Shares | $919,863,000 | $697,312,000 | $508,636,000 | $399,900,000 |
| Diluted NI Availto Com Stockholders | $-351,398,000 | $-413,564,000 | $-583,196,000 | $-416,567,000 |
| Minority Interests | $74,000 | $81,000 | $656,000 | $753,000 |
| Tax Provision | $-135,000 | $0 | $-40,000 | $34,000 |
| Impairment Of Capital Assets | $0 | $0 | $886,000 | $681,000 |
| Gain On Sale Of Security | $59,203,000 | $39,007,000 | $-47,332,000 | $7,662,000 |
| Research And Development | $218,559,000 | $190,144,000 | $232,366,000 | $248,149,000 |
| Selling General And Administration | $150,003,000 | $168,783,000 | $129,620,000 | $102,708,000 |
| Securities Amortization | - | - | $-1,844,000 | $1,486,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-514,422,000 | $-505,031,000 | $-604,080,000 | $-467,330,000 |
| Total Assets | $501,898,000 | $382,933,000 | $504,452,000 | $362,356,000 |
| Total Non Current Assets | $187,023,000 | $198,347,000 | $210,368,000 | $221,779,000 |
| Other Non Current Assets | $18,416,000 | $4,827,000 | $2,880,000 | $4,860,000 |
| Non Current Note Receivables | $7,380,000 | $7,130,000 | $6,879,000 | $6,629,000 |
| Goodwill And Other Intangible Assets | $13,953,000 | $15,933,000 | $17,093,000 | $20,003,000 |
| Other Intangible Assets | $13,043,000 | $15,023,000 | $17,093,000 | $20,003,000 |
| Current Assets | $314,875,000 | $184,586,000 | $294,084,000 | $140,577,000 |
| Other Current Assets | $2,135,000 | $1,303,000 | $2,625,000 | $2,899,000 |
| Prepaid Assets | $26,395,000 | $22,549,000 | $21,829,000 | $28,604,000 |
| Inventory | $910,000 | $8,272,000 | $0 | - |
| Receivables | $42,617,000 | $2,653,000 | $3,168,000 | $1,890,000 |
| Accounts Receivable | $42,571,000 | $2,360,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $242,818,000 | $149,809,000 | $266,462,000 | $107,184,000 |
| Cash And Cash Equivalents | $88,334,000 | $143,428,000 | $265,453,000 | $104,641,000 |
| Investmentin Financial Assets | - | $0 | $891,000 | $840,000 |
| Other Receivables | - | - | $1,149,000 | - |
| Debt | ||||
| Net Debt | $388,759,000 | $318,449,000 | $416,084,000 | $568,531,000 |
| Total Debt | $518,075,000 | $504,166,000 | $726,723,000 | $723,773,000 |
| Long Term Debt And Capital Lease Obligation | $510,540,000 | $496,700,000 | $721,479,000 | $289,222,000 |
| Long Term Debt | $477,093,000 | $461,877,000 | $681,537,000 | $241,271,000 |
| Current Debt And Capital Lease Obligation | $7,535,000 | $7,466,000 | $5,244,000 | $434,551,000 |
| Current Debt | - | - | - | $431,901,000 |
| Other Current Borrowings | - | - | - | $431,901,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,001,472,000 | $871,062,000 | $1,090,389,000 | $812,176,000 |
| Total Non Current Liabilities Net Minority Interest | $939,718,000 | $816,118,000 | $1,032,106,000 | $311,315,000 |
| Other Non Current Liabilities | $325,039,000 | $284,723,000 | $156,524,000 | $457,000 |
| Derivative Product Liabilities | $104,139,000 | $34,695,000 | $154,103,000 | $21,636,000 |
| Current Liabilities | $61,754,000 | $54,944,000 | $58,283,000 | $500,861,000 |
| Other Current Liabilities | $3,073,000 | $1,050,000 | $716,000 | $1,628,000 |
| Payables And Accrued Expenses | $31,078,000 | $31,403,000 | $34,732,000 | $46,574,000 |
| Payables | $7,381,000 | $6,898,000 | $10,331,000 | $24,485,000 |
| Accounts Payable | $6,978,000 | $6,725,000 | $9,195,000 | $21,016,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-500,469,000 | $-489,098,000 | $-586,987,000 | $-447,327,000 |
| Total Equity Gross Minority Interest | $-499,574,000 | $-488,129,000 | $-585,937,000 | $-449,820,000 |
| Stockholders Equity | $-500,469,000 | $-489,098,000 | $-586,987,000 | $-447,327,000 |
| Gains Losses Not Affecting Retained Earnings | $28,956,000 | $1,198,000 | $10,000 | $183,000 |
| Other Equity Adjustments | $28,956,000 | $1,198,000 | $10,000 | $183,000 |
| Retained Earnings | $-3,726,646,000 | $-3,375,248,000 | $-2,961,684,000 | $-2,378,488,000 |
| Long Term Equity Investment | - | - | - | $840,000 |
| Other | ||||
| Treasury Shares Number | $163,800 | $163,800 | $163,800 | $163,800 |
| Ordinary Shares Number | $1,011,800,008 | $852,904,340 | $670,867,344 | $421,569,115 |
| Share Issued | $1,011,963,808 | $853,068,140 | $671,031,144 | $421,732,915 |
| Tangible Book Value | $-514,422,000 | $-505,031,000 | $-604,080,000 | $-467,330,000 |
| Invested Capital | $-23,376,000 | $-27,221,000 | $94,550,000 | $225,845,000 |
| Working Capital | $253,121,000 | $129,642,000 | $235,801,000 | $-360,284,000 |
| Capital Lease Obligations | $40,982,000 | $42,289,000 | $45,186,000 | $50,601,000 |
| Total Capitalization | $-23,376,000 | $-27,221,000 | $94,550,000 | $-206,056,000 |
| Minority Interest | $895,000 | $969,000 | $1,050,000 | $-2,493,000 |
| Additional Paid In Capital | $3,197,120,000 | $2,884,867,000 | $2,374,620,000 | $1,930,936,000 |
| Capital Stock | $101,000 | $85,000 | $67,000 | $42,000 |
| Common Stock | $101,000 | $85,000 | $67,000 | $42,000 |
| Long Term Capital Lease Obligation | $33,447,000 | $34,823,000 | $39,942,000 | $47,951,000 |
| Current Capital Lease Obligation | $7,535,000 | $7,466,000 | $5,244,000 | $2,650,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $20,068,000 | $15,025,000 | $17,591,000 | $18,108,000 |
| Current Accrued Expenses | $23,697,000 | $24,505,000 | $24,401,000 | $22,089,000 |
| Dueto Related Parties Current | $403,000 | $173,000 | $1,136,000 | $3,469,000 |
| Goodwill | $910,000 | $910,000 | - | - |
| Net PPE | $147,274,000 | $170,457,000 | $182,625,000 | $189,447,000 |
| Accumulated Depreciation | $-112,485,000 | $-99,589,000 | $-84,376,000 | $-69,252,000 |
| Gross PPE | $259,759,000 | $270,046,000 | $267,001,000 | $258,699,000 |
| Leases | $73,141,000 | $73,126,000 | $72,552,000 | $68,710,000 |
| Construction In Progress | $86,433,000 | $86,417,000 | $84,436,000 | $72,693,000 |
| Other Properties | $96,269,000 | $106,941,000 | $106,458,000 | $113,733,000 |
| Machinery Furniture Equipment | $3,916,000 | $3,562,000 | $3,555,000 | $3,563,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $46,000 | $293,000 | $2,019,000 | $1,890,000 |
| Other Short Term Investments | $154,484,000 | $6,381,000 | $1,009,000 | $2,543,000 |
| Investments And Advances | - | $0 | $891,000 | $840,000 |
| Finished Goods | - | $767,000 | $0 | - |
| Work In Process | - | $7,505,000 | $0 | - |
| Raw Materials | - | $0 | $0 | - |
| Available For Sale Securities | - | - | $891,000 | $840,000 |
| Other Investments | - | - | - | $4,860,000 |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-309,188,000 | $-398,124,000 | $-397,341,000 | $-436,900,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-304,936,000 | $-391,236,000 | $-366,757,000 | $-337,509,000 |
| Cash Flow From Continuing Operating Activities | $-304,936,000 | $-391,236,000 | $-366,757,000 | $-337,509,000 |
| Operating Gains Losses | $-53,320,000 | $-33,432,000 | $49,610,000 | $-13,460,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,252,000 | $-6,888,000 | $-30,584,000 | $-99,391,000 |
| Investing Cash Flow | $-149,801,000 | $-12,246,000 | $-30,470,000 | $27,297,000 |
| Cash Flow From Continuing Investing Activities | $-149,801,000 | $-12,246,000 | $-30,470,000 | $27,297,000 |
| Net Other Investing Changes | - | $-1,000,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $400,562,000 | $111,357,000 | $100,561,000 | $60,427,000 |
| Financing Cash Flow | $400,241,000 | $281,630,000 | $558,341,000 | $233,613,000 |
| Cash Flow From Continuing Financing Activities | $400,241,000 | $281,630,000 | $558,341,000 | $233,613,000 |
| Net Other Financing Charges | $-1,132,000 | $96,956,000 | $192,764,000 | $-339,000 |
| Net Common Stock Issuance | $400,562,000 | $111,357,000 | $100,561,000 | $60,427,000 |
| Common Stock Issuance | $400,562,000 | $111,357,000 | $100,561,000 | $60,427,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-28,000 | $-64,000 | $-77,000 | $-58,000 |
| Issuance Of Debt | $2,884,000 | $0 | $258,700,000 | $174,125,000 |
| Interest Paid Supplemental Data | $71,321,000 | $92,318,000 | $77,192,000 | $35,442,000 |
| Income Tax Paid Supplemental Data | $0 | $15,000 | $8,000 | $2,000 |
| End Cash Position | $89,431,000 | $143,912,000 | $265,787,000 | $104,965,000 |
| Beginning Cash Position | $143,912,000 | $265,787,000 | $104,965,000 | $181,280,000 |
| Effect Of Exchange Rate Changes | $15,000 | $-23,000 | $-292,000 | $284,000 |
| Changes In Cash | $-54,496,000 | $-121,852,000 | $161,114,000 | $-76,599,000 |
| Proceeds From Stock Option Exercised | $-2,045,000 | $73,381,000 | $6,393,000 | $-542,000 |
| Net Issuance Payments Of Debt | $2,856,000 | $-64,000 | $258,623,000 | $174,067,000 |
| Net Short Term Debt Issuance | $2,884,000 | $0 | $0 | $174,125,000 |
| Short Term Debt Issuance | $2,884,000 | $0 | $0 | $174,125,000 |
| Net Long Term Debt Issuance | $-28,000 | $-64,000 | $258,623,000 | $174,067,000 |
| Long Term Debt Payments | $-28,000 | $-64,000 | $-77,000 | $-58,000 |
| Long Term Debt Issuance | $0 | $0 | $258,700,000 | $174,125,000 |
| Net Investment Purchase And Sale | $-145,549,000 | $-4,358,000 | $114,000 | $127,688,000 |
| Sale Of Investment | $95,824,000 | $136,607,000 | $10,472,000 | $162,000,000 |
| Purchase Of Investment | $-241,373,000 | $-140,965,000 | $-10,358,000 | $-34,312,000 |
| Net Intangibles Purchase And Sale | $-406,000 | $0 | $0 | $-21,229,000 |
| Purchase Of Intangibles | $-406,000 | $0 | $0 | $-21,229,000 |
| Net PPE Purchase And Sale | $-3,846,000 | $-6,888,000 | $-30,584,000 | $-78,162,000 |
| Purchase Of PPE | $-3,846,000 | $-6,888,000 | $-30,584,000 | $-78,162,000 |
| Change In Working Capital | $-54,329,000 | $-19,422,000 | $3,828,000 | $-8,001,000 |
| Change In Other Working Capital | $477,000 | $763,000 | $-1,129,000 | $-1,225,000 |
| Change In Other Current Liabilities | $-7,210,000 | $-5,473,000 | $-2,978,000 | $-4,319,000 |
| Change In Other Current Assets | $803,000 | $-1,108,000 | $1,764,000 | $1,998,000 |
| Change In Payables And Accrued Expense | $2,994,000 | $-4,675,000 | $213,000 | $12,102,000 |
| Change In Accrued Expense | $3,184,000 | $-1,508,000 | $6,689,000 | $4,102,000 |
| Change In Payable | $-190,000 | $-3,167,000 | $-6,476,000 | $8,000,000 |
| Change In Account Payable | $-190,000 | $-3,167,000 | $-6,476,000 | $8,000,000 |
| Change In Prepaid Assets | $-4,857,000 | $1,703,000 | $5,958,000 | $-16,557,000 |
| Change In Inventory | $-6,325,000 | $-8,272,000 | $0 | $0 |
| Change In Receivables | $-40,211,000 | $-2,360,000 | $0 | $0 |
| Changes In Account Receivables | $-40,211,000 | $-2,360,000 | $0 | $0 |
| Other Non Cash Items | $90,578,000 | $24,134,000 | $93,642,000 | $35,311,000 |
| Stock Based Compensation | $36,809,000 | $34,432,000 | $49,163,000 | $40,179,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $632,000 | $1,591,000 | $4,190,000 |
| Asset Impairment Charge | $14,018,000 | $0 | $886,000 | $2,014,000 |
| Amortization Of Securities | $-2,745,000 | $-1,489,000 | $-137,000 | $1,318,000 |
| Depreciation Amortization Depletion | $15,525,000 | $17,554,000 | $18,512,000 | $18,260,000 |
| Depreciation And Amortization | $15,525,000 | $17,554,000 | $18,512,000 | $18,260,000 |
| Gain Loss On Investment Securities | $-53,320,000 | $-33,432,000 | $49,610,000 | $-13,460,000 |
| Net Income From Continuing Operations | $-351,472,000 | $-413,645,000 | $-583,852,000 | $-417,320,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-1,000,000 |
| Purchase Of Business | - | $0 | $0 | $-1,000,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Deferred Tax | - | - | - | $-4,000 |
| Deferred Income Tax | - | - | - | $-4,000 |
| Common Stock Payments | - | - | - | - |
| Earnings Losses From Equity Investments | - | - | - | - |
Fetched: 2026-06-20